A Cell Line for Detection of Botulinum Neurotoxin Type B by Rust, A. et al.
fphar-08-00796 November 5, 2017 Time: 18:13 # 1
ORIGINAL RESEARCH


















†These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Integrative and Regenerative
Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 22 September 2017
Accepted: 20 October 2017
Published: 09 November 2017
Citation:
Rust A, Doran C, Hart R, Binz T,
Stickings P, Sesardic D, Peden AA
and Davletov B (2017) A Cell Line
for Detection of Botulinum Neurotoxin
Type B. Front. Pharmacol. 8:796.
doi: 10.3389/fphar.2017.00796
A Cell Line for Detection of
Botulinum Neurotoxin Type B
Aleksander Rust1†, Ciara Doran1†, Rosalyn Hart1, Thomas Binz2, Paul Stickings3,
Dorothea Sesardic3, Andrew A. Peden1* and Bazbek Davletov1*
1 Department of Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom, 2 Institut für Zellbiochemie,
Medizinische Hochschule Hannover, Hannover, Germany, 3 Division of Bacteriology, National Institute for Biological
Standards and Control, Medicines and Healthcare Product Regulatory Agency, Potters Bar, United Kingdom
Botulinum neurotoxins (BoNTs) type A and type B are commonly used as
biopharmaceutics for neurological diseases, uniquely allowing months-long paralysis
of target muscles. Their exquisite neuronal specificity is conferred by a multistep
process of binding, internalization, cytosolic escape and cleavage of the neuron-specific
proteins, SNAP-25 and vesicle-associated membrane proteins (VAMPs), ultimately to
inhibit secretion of neurotransmitters. Currently the mouse lethality bioassay is the
only available method for quality control testing of VAMP-cleaving botulinum products.
Refined assays for botulinum product testing are urgently needed. Specifically, in vitro
replacement assays which can account for all steps of BoNT intoxication are in high
demand. Here, we describe a novel SiMa cell-based approach where re-engineering
of the VAMP molecule allows detection of all BoNT/B intoxication steps using a
luminescent enzymatic reaction with sensitivity comparable to mouse LD50 bioassay.
The presented one-step enzyme-linked immunosorbent assay meets 3Rs (replacement,
reduction, and refinement of the use of animals) objectives, is user-friendly and will
accelerate development of new botulinum drugs. The sensitive enzymatic reporter cell
line could also be adapted for the detection of toxin activity during the manufacture of
botulinum and tetanus vaccines.
Keywords: botulinum neurotoxin type B, botulinum neurotoxin-sensitive cell line, SiMa neuroblastoma, VAMP,
tetanus, luciferase, Myobloc, 3Rs
INTRODUCTION
Botulinum neurotoxins (BoNTs) are produced by anaerobic bacteria of the genus Clostridium
and are responsible for the deadly disease called botulism manifested by neuromuscular paralysis
(Erbguth and Naumann, 1999; Schiavo et al., 2000; Montecucco and Molgó, 2005). In the last
three decades, BoNTs have been utilized widely in many medical applications when injected
locally and in small doses (Davletov et al., 2005; Chaddock and Marks, 2006; Foster et al., 2006).
A typical BoNT is expressed by bacteria as a single chain precursor protein that is processed into
two polypeptide chains – a 100 kD heavy chain consisting of the receptor-binding domain and
the translocation domain which is linked via a disulphide bond to 50 kD light chain, a SNARE
protease (Lacy et al., 1998; Chaddock and Marks, 2006; Binz and Rummel, 2009). Among seven
commonly known BoNT serotypes (A–G) BoNT/A, C, and E proteolyse SNAP-25, while BoNT/B,
D, F, and G cleave vesicle-associated membrane proteins (VAMPs) also known as synaptobrevins
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(Lacy and Stevens, 1999; Schiavo et al., 2000; Rummel et al.,
2004; Antonucci et al., 2008; Rossetto and Montecucco, 2008;
Binz et al., 2010). In order to reach their intraneuronal
substrates, BoNTs first bind neuronal surface gangliosides
and then a synaptic vesicle protein (synaptotagmin or SV2)
on the presynaptic membrane for subsequent internalization
(Montecucco and Schiavo, 1994; Binz and Rummel, 2009). Once
the internalized vesicle acidifies, the botulinum translocation
domain changes conformation to form a putative protein
transduction channel that enables translocation of the protease
into the cytosol following reduction of the disulphide bond
(Koriazova and Montal, 2003; Puhar et al., 2004; Pirazzini et al.,
2013).
Pharmaceutical BoNT/A (e.g., Botox R©) and BoNT/B (e.g.,
Myobloc R©, Neurobloc R©) products are mainly licensed for the
treatment of neuromuscular spasms, but their use is expanding
to other conditions such as hyperhidrosis, bladder dysfunction,
spasmodic dysphonia, sialorrhoea, anal fissures, piriformis
syndrome, various pain conditions, and cosmetic applications.
As a “biologic” medicine, each new batch of BoNT is considered
a new product and must undergo rigorous potency, quality
and safety testing before market release. In addition assays
are needed for confirmation of natural cases of botulism, in
food testing and prevention of both human- and animal-
targeted bioterrorism. Currently the “gold standard” toxicity test
is the mouse LD50 lethality bioassay. This has many serious
disadvantages including imprecision, necessitating the use of
many laboratory animals (Sesardic et al., 2003), along with animal
suffering due to the lethal endpoint, high operational cost, and
lack of specificity since all BoNT serotypes will cause similar
muscular paralysis. Therefore, more precise replacement assays
that follow the principles of the 3Rs (reduction, replacement,
and refinement of animal use in research) are urgently needed.
An ideal replacement assay must faithfully represent all the
biological steps of BoNT action. Such a replacement method has
been recently developed for BoNT/A type products where SiMa
neuroblastoma cell line is being adapted as cell based potency
assay for Botox R© (Fernández-Salas et al., 2012). The assay format
is a sensitive sandwich enzyme-linked immunosorbent assay,
ELISA, detecting a stable BoNT/A-cleaved SNAP-25 product.
To date, however, there are no cell-based assays for testing
BoNT/B which proteolyses VAMP molecules. Here, we describe
an in vitro assay using the SiMa cell line (Marini et al.,
1999) that has been engineered to carry a stabilized VAMP
molecule to report the BoNT/B activity via a luminescent
reaction.
RESULTS
Introduction of Stabilized VAMP2 into the
SiMa Neuroblastoma Cell Line for
BoNT/B Detection
We tested several candidate neuronal cell lines – SiMa, SH-
SY5Y, IMR-32, and N2A – for expression of the BoNT/B
target, VAMP2. Figure 1A illustrates that only the N2A cell
line expressed VAMP2. We tested N2A cells for sensitivity to
BoNT/B using Western immunoblotting for cleavage of VAMP2.
Figure 1B shows that no cleavage was detected when the
cells were incubated with concentrations as high as 30 nM
BoNT/B. However, when BoNT/B entry was facilitated by
Lipofectamine 3000 (Rust et al., 2016), we observed dose-
dependent disappearance of VAMP2, indicating that BoNT/B
can cleave VAMP2 but is unable to enter N2A cells. Following
BoNT/B-induced cleavage there were no VAMP2 breakdown
products (Figure 1C) most likely due to their immediate
degradation by intracellular clearance mechanisms (Foran et al.,
2003b). Degradation of the fragments of VAMP2 precludes the
direct detection of botulinum-cleaved fragment necessitating
novel synthetic approaches.
Recently, Fernández-Salas et al. (2012) developed a cell-based
assay specifically for testing the stability and potency of BoNT/A
using SiMa neuroblastoma cells. We have also recently reported
that SiMa cells can be used to detect BoNT type C activity in
the picomolar range (Rust et al., 2016). We therefore tested this
neuroblastoma cell line for the presence of BoNT/B receptors –
synaptotagmin 1 and the ganglioside GT1b. Immunoblotting
revealed that both N2A and SiMa cells express synaptotagmin 1.
In contrast, Figure 1C shows that SiMa but not N2A cells are
immunopositive for the complex ganglioside GT1b. This is in
agreement with previous studies showing that N2A cells lack
the neuronal gangliosides necessary for BoNT entry (Yowler
et al., 2002) and protein transduction methods are required to
introduce the botulinum proteolytic domains (Arsenault et al.,
2014).
Since both N2A and SiMa express some of the necessary
components for BoNT/B sensitivity, but lack others, we
postulated that we could engineer a BoNT/B sensitive cell
line by a synthetic gene approach. Ganglioside biosynthesis
requires a complex, multigenic mechanism (Yu et al., 2011),
making N2A less amenable to engineering. We hypothesized
that SiMa cells could report BoNT/B activity if we introduce
an engineered VAMP2 exogenously. Therefore, we generated a
SiMa cell line stably expressing GFP-VAMP2 using retroviral
transduction followed by puromycin selection. We used a fusion
protein construct that has GFP inserted at the amino terminus of
VAMP2 (Figure 2A) such that GFP will be anchored to vesicles
facing the cytosol. At high magnification, GFP-VAMP2 exhibits a
punctate distribution in SiMa cells, consistent with the predicted
localisation to vesicular structures (Figure 2B, upper). When
the cells were incubated with BoNT/B (30 nM), the pattern of
GFP expression became diffuse (Figure 2B, bottom) consistent
with cleavage of VAMP2 by the botulinum protease followed
by the release of GFP from vesicles into the cytosol. Following
puromycin selection all of SiMa cells were positive for GFP-
VAMP2, as evidenced by fluorescent microscopy (Figure 2C).
The native VAMP2 is quickly degraded in neurons once cleaved
at a single position by BoNTs. Importantly, immunoblotting
revealed that a band corresponding to the cleaved GFP-VAMP2
product is completely stable in the neuroblastoma cell line
(Figure 2D), indicating that the GFP added to the N-terminal end
of VAMP2 somehow prevents degradation offering the possibility
to measure the botulinum-cleaved VAMP2 product.
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FIGURE 1 | BoNT/A-sensitive SiMa neuroblastoma cell line expresses neuronal gangliosides and synaptotagmin but not BoNT/B substrate VAMP2. (A) Three
neuroblastoma cells (SiMa, SH-SY5Y and IMR-32) express the BoNT/A substrate SNAP25 but not the BoNT/B target VAMP2. Only the N2A neuroblastoma cell line
expresses both SNAP25 and VAMP2. (B) BoNT/B does not cleave VAMP2 in N2A cells at indicated concentrations. Transduction of BoNT/B into N2A cells using
Lipofectamine LF3000 (LF3000) allows VAMP2 cleavage. Note the absence of VAMP fragments at all BoNT/B concentrations. (C) A polyclonal antibody against
synaptotagmin 1 reveals its presence in the SiMa and N2A cell lines. (D) The SiMa but not N2A cell line expresses neuronal ganglioside GT1b as revealed by specific
anti-GT1b antibody.
FIGURE 2 | Generation of GFP-VAMP2 SiMa cell line using viral transduction. (A) Schematic showing the fusion protein containing GFP inserted at the amino
terminus of VAMP2. TMR, transmembrane region. (B) GFP-VAMP2 localizes to vesicular structures (top) and is released into the cytosol (bottom) upon incubation
with BoNT/B (30 nM). (C) Robust expression following viral transduction and puromycin selection is evident in GFP and differential interference contrast (DIC) merged
images. (D) Stable GFP-VAMP2 cleavage product can be detected following incubation with BoNT/B (30 nM). Immunoblotting was performed using a GFP antibody.
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Generation of a BoNT/B-Sensitive
Enzymatic Reporter Cell Line
While our GFP-VAMP2 cell line offers a possibility to develop
a “high content” analysis assay using automated microscopy
or sandwich ELISA-based detection as described for BoNT/A-
cleaved SNAP25 (Fernández-Salas et al., 2012), we hypothesized
that a direct linkage of an enzyme to the VAMP molecule
will allow faster and easier detection of BoNT/B activity
if we can capture the proteolytic product on microplates.
One-step capture immunoassay utilizing enzymatic reporter
molecules offers the dual advantage of fewer washing and
incubation steps coupled with superior sensitivity due to signal
amplification (Boute et al., 2016). Using viral transduction we
generated two stable cell lines expressing either peroxidase- or
luciferase-linked VAMP2 products, namely APEX2-VAMP2
and NanoLuc-VAMP2, respectively. Both constructs also
carry a hemagglutinin-related HA tag allowing a convenient
immunological detection (Figure 3A). Immunocytochemistry
revealed that both constructs exhibited robust expression
inside SiMa cells (Figure 3B). The engineered cells were then
differentiated and incubated with BoNT/B (10 nM) for 48 h
before evaluation of the VAMP2 cleavage by immunoblotting
with an antibody against VAMP2. Two bands, corresponding to
cleaved and uncleaved VAMP2 molecules, were readily detectable
in the NanoLuc-VAMP2 cell line (Figure 3C). Curiously, we
could not detect any cleavage in the APEX2-VAMP2 cell line
(Figure 3C), which may be explained by steric hindrance
introduced by a relatively large peroxidase enzyme.
BoNT/B Detection Using a
Cleavage-Specific Antibody and the
NanoLuc-VAMP Assay
The stabilized BoNT/B-cleaved substrates offer the opportunity
to detect the BoNT/B-cleaved fragment using cleavage-specific
antibody directed against the cleaved end of the VAMP2
molecule. We generated a rabbit BoNT/B-cleaved VAMP
antibody using the peptide antigen sequence shown in Figure 4A.
We tested the ability of the cleaved VAMP antibody to detect
the cleaved product following application of BoNT/B to the
engineered SiMa cells. Figure 4B shows that application of
increasing doses of BoNT/B led to increased immunoblotting
signal corresponding to the 28 kD NanoLuc-VAMP2 cleavage
product being detected by the cleaved VAMP antibody. No
signal was detectable in the vehicle control sample, consistent
with antibody specificity for the cleaved VAMP product only.
Figure 4C shows densitometry quantification of dose-dependent
sensitivity of immunoblotting using the cleaved VAMP2 antibody
with limit of detection being 300 pM BoNT/B in differentiated
SiMa cells.
Next we explored luminescent detection which is afforded
by the NanoLuc-VAMP2 construct using a highly sensitivity
NanoGlo reaction and commercial BoNT/B with a known mouse
LD50 activity (Metabiologics, United States). We immobilized
the cleaved-VAMP2 antibody on Protein A-coated 96-well plates
and evaluated the detection range of BoNT/B activity in one-step
ELISA format (Figure 5A). BoNT/B with known LD50 activity
was applied to the engineered SiMa cells at a wide range of
concentrations for 60 h and the generated NanoLuc-VAMP2
fragment was captured on the cleaved-VAMP2 antibody plates.
Following washing the wells were filled with NanoGlo solution
and luminescent signal was read in a plate luminometer. The one-
step ELISA showed NanoLuc-VAMP detection sensitivity similar
to the mouse LD50 specified by the manufacturer (Figure 5B).
Importantly, BoNT/B activity was detectable in one-step ELISA
assay even at the lowest dose tested of 0.1 mouse LD50, which
corresponds to∼20 fM BoNT/B (Figure 5C).
DISCUSSION
Despite their distinction as the most lethal toxins known
to man, BoNTs are increasingly being harnessed to treat a
range of previously intractable neuromuscular and neurological
conditions. The neuronal specificity of the seven different BoNT
serotypes is an active area of investigation, however, they all
share a general mechanism of action, which has evolved to
specifically target the nervous system. This comprises toxin
binding to a cell surface receptor, internalization of the toxin-
receptor complex, light chain translocation into the cytoplasm
and proteolytic cleavage of a SNARE protein, ultimately to inhibit
the exocytosis machinery (Foran et al., 2003a). A wide variety
of biochemical in vitro assays for BoNT toxicity testing have
been developed to reduce and replace current in vivo lethality
assays. Single parameter assays, e.g., SNARE cleavage assay or
ganglioside binding, are unfortunately unable to distinguish
between biologically active and inactive BoNTs. Recently, a dual
parameter BINACLE (binding and cleavage) assay has been
reported to offer detection limit of less than 1 pg/ml, equivalent to
less than 0.1 mouse LD50 units/ml of BoNT/B (Wild et al., 2016).
One specific limitation is that the biochemical BINACLE assay
takes into account only receptor binding and the VAMP cleavage
steps of intoxication without probing the cellular translocation
function and therefore cannot fully replace the mouse bioassay
in the quality control of pharmaceutical products. It is generally
agreed that in the context of pharmacological botulinum product
testing, a cell-based assay encompassing all steps of BoNT action
shall be developed to replace the rodent lethality assays. The ‘gold
standard’ mouse bioassays are exquisitely sensitive to BoNT/A
and BoNT/B (10–30 pg/ml) (Wictome et al., 1999; Ferreira
et al., 2004) and it has been a great challenge in the field to
find alternatives. Recently, cell-based assays have been approved
by regulatory authorities for pharmaceutical BoNT/A testing
(Fernández-Salas et al., 2012; Merz, 2015). However, currently
there are no equivalent cell assays for BoNT/B. For BoNT/B,
the best reported EC50 values in primary cells were reported
in rat spinal cord neurons with an EC50 of ∼29 mouse LD50
units (Whitemarsh et al., 2012), which is only in a low pM
range. One major drawback of using primary cells is that they
must be matured in culture for 2 weeks. Moreover, they are
not favored by regulatory agencies because of their inherent
biological variability (Adler et al., 2010). Human induced
pluripotent stem cells (hiPSCs) derived neurones can exceed the
sensitivity of primary cells, however, the best reported sensitivity
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FIGURE 3 | Generation of stable SiMa cell lines with VAMP2 fusions to peroxidase APEX2 and luciferase NanoLuc. (A) Immunoblot showing expression of APEX2-
and NanoLuc-VAMP2 constructs in SiMa cells with expected molecular weights of ∼45 kD and ∼30 kD. Both constructs carry the HA tag as evidenced by
immunoblotting. (B) The fusion proteins exhibit robust expression as revealed by immunocytochemical analysis using antibodies against the HA-tag. (C) Immunoblot
demonstrating that the APEX2-VAMP2 reporter molecule is resistant to cleavage by BoNT/B (10 nM), whereas VAMP cleavage is detectable in the differentiated
NanoLuc-VAMP2 cells. The arrow indicates the cleaved product.
for BoNT/B in hiPSCs was ∼16 mouse LD50 units (Whitemarsh
et al., 2012). Moreover, if purchased undifferentiated, hiPSCs
require 3–4 weeks for maturation with considerable hands-on
manipulation and specialized expertise. It is possible to purchase
pre-differentiated hiPSCs, but, currently, costs are prohibitive
for wide-spread adaption. Western immunoblotting detecting
disappearance of native neuronal VAMP2 is also not optimal
for accurate quantification. Indeed, detection of appearance of
cleavage product is much better suited for assay development as
demonstrated by SNAP25 cleavage assay in the case of BoNT/A
(Fernández-Salas et al., 2012). Here, we described a novel
approach for BoNT/B detection assay using a continuous cell line
carrying a stabilized VAMP2 cleavage reporter. Our NanoLuc-
VAMP2 SiMa neuroblastoma assay far exceeds the rat spinal
cord cell sensitivity using a very simple 3-day differentiation
protocol. It appears that the differentiated SiMa neuroblastoma
cells are sensitive to BoNTs (Fernández-Salas et al., 2012; Rust
et al., 2016; Bak et al., 2017) due to the high level of expression of
neuron-specific GT1b ganglioside (Figure 1D) which is essential
for the initial binding of the toxins (Montecucco and Schiavo,
1994; Binz and Rummel, 2009). If needed, sensitivity could
be improved further by stably transfecting into the NanoLuc-
VAMP2 SiMa neuroblastoma cells the mouse synaptotagmin 2
which has 10 times higher affinity to BoNT/B compared to
human synaptotagmin (Strotmeier et al., 2012). Subcloning of
the parental SiMa cell line and clonal screening for highest
sensitivity to BoNT/B offers a possibility to further enhance
the one-step ELISA for BoNT/B detection. Finally, optimisation
of SiMa differentiation protocol using well established methods
could be also tested to increase BoNT/B sensitivity if required.
In summary, the NanoLuc-VAMP reporter cell assay has
the potential to offer an accurate replacement for the BoNT/B
mouse bioassay in a homogeneous cell line with excellent
sensitivity. The main advantage of the described method is
that unlike in neurons, the NanoLuc-VAMP2 cleavage product
evades degradation following cleavage by BoNT/B offering a
highly specific and sensitive enzymatic read-out of BoNT/B
activity. The assay may well be suited for measuring potency
of pharmaceutical BoNT/B products and antitoxin antibodies in
toxin neutralization testing. The presented assay could be adapted
to other VAMP2-cleaving BoNT serotypes and also tetanus toxin
(Schiavo et al., 2000) to replace the animal lethality tests used
during production of botulinum and globally essential tetanus
vaccines.
MATERIALS AND METHODS
Cell Culture, Differentiation, and
Generation of VAMP2 SiMa Cell Lines
SiMa cells (DSMZ) were grown in RPMI media (Life
Technologies) supplemented with 10% fetal bovine serum
(FBS) (Life Technologies). IMR32 and N2A cells (Sigma)
were grown in DMEM media (Life Technologies) with 10%
FBS. SH-SY5Y cells (Sigma) were grown in 1:1 mix of MEM
(Life Technologies) and F12 nutrient mix (Life Technologies)
supplemented with 15% FBS and 1% non-essential amino acids
(NEAA) (Life Technologies). Cells were maintained at 37◦C, 5%
CO2. Cell lines were kept frozen after receiving from supplier
and were not used for more than 20 passages (10 weeks).
For differentiation, plates were pre-coated with 10 µg/ml
laminin (Sigma) and left at 37◦C for at least 1 h before washing
twice with phosphate buffer saline (PBS). Wild-type and modified
SiMa cell lines were seeded at a density of 1 × 104 cells per well
in 96-well plates or 1 × 105 cells per well in 48-well plates and
differentiated for 72 h. SH-SY5Y, IMR-32, and N2A cells were
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FIGURE 4 | Detection of BoNT/B activity in NanoLuc-VAMP2 SiMa cells using
specific BoNT/B-cleaved VAMP2 antibody. (A) The VAMP2 amino acid
sequence used for generation of the rabbit polyclonal antibody is underlined.
The arrow indicates the cleavage site by BoNT/B. (B) Immunoblot showing
dose-dependent increase of BoNT/B-cleaved NanoLuc-VAMP2 product using
the cleaved VAMP2 antibody. Engineered SiMa cells were incubated for 60 h
in the presence of indicated concentrations of BoNT/B followed by
SDS–PAGE and immunoblotting. (C) Graph showing quantification of
dose-dependent increase in cleaved VAMP2 immunoblotting signal in
response to BoNT/B with sensitivity in the low picomolar range (n = 3 ± SD).
seeded at 5 × 103 cells for 96-well plates and 2 × 104 cells for
48-well plates and differentiated for 144 h. For experiments with
all wild-type neuroblastoma cell lines and modified SiMa cells,
the following differentiation medium was used: RPMI, 1X B-27
(Life Technologies), 1 mM HEPES, pH 7.2 (Fisher), 1% NEAA
and 10 µM all-trans-retinoic acid (Sigma). SiMa and modified
SiMa were differentiated for 72 h.
GFP-VAMP2, APEX2-VAMP2, and NanoLuc-VAMP2 were
generated and cloned into the retroviral expression vector
pQCXIP (Clontech). The constructs were transduced into SiMa
cells using VSV-G pseudotyped viral particles produced in
HEK293T cells (Swift et al., 2001). Stable expression of the
reporter constructs was achieved by selecting the transduced cells
with 1 µg/ml puromycin.
Toxins
Recombinant BoNT/B was expressed in Escherichia coli using
pBoNTBs-throm (BoNT/B gene cloned from strain Okra,
subtype B1). The plasmid is a derivative of pBoNTBs (Rummel
et al., 2004) encoding a thrombin cleavage site (TKSLVPRGS)
integrated between the light and heavy chains at position K441–
A442. BoNT/B was purified by means of its C-terminal Strep-tag
and activated using thrombin. Coomassie stained protein had a
purity of >95% and a degree of activation of >98%. Recombinant
BoNT/B was delivered into N2A cells using Lipofectamine 3000
(Life Technologies) as described previously (Arsenault et al.,
2014). For direct comparison of our method with the mouse
lethality assay we used BoNT/B (Metabiologics, United States)
with a molecular weight of 150 kD and a known specific activity
of 1.25 × 108 mouse LD50/mg as defined by the manufacturer.
Handling procedures for BoNT/B (including the use of double
gloves, avoidance of needles, class 2 safety cabinet) were approved
by the Health and Safety Committee of the University of
Sheffield. On completion of experiments, BoNT/B and BoNT/B-
contaminated samples were inactivated by an acid/detergent
mixture followed by incineration.
Antibody Generation and Western
Immunoblotting
The rabbit polyclonal antibody to BoNT/B-cleaved VAMP2
was made and affinity purified using the peptide antigen
FIGURE 5 | One-step ELISA assay using the NanoLuc-VAMP2 construct. (A) Schematic (left) showing the principle of one-step ELISA. The cleaved VAMP2
antibody was immobilized on Protein A plates for capture of the BoNT/B-cleaved VAMP2 construct. (B) Graph showing the dose-dependent detection of
NanoLuc-VAMP2 cleavage by Metabiologics BoNT/B (n = 3 ± SD). (C) The NanoLuc assay allows detection of the VAMP cleavage by BoNT/B at 0.1 mouse LD50
above the baseline (n = 3 ± SD, ∗∗p < 0.01, Student’s t-test).
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sequence K- ALQAGASQ (Davids Biotechnologie, Germany).
Immunoblotting was performed as described previously
(Arsenault et al., 2014). Briefly, cells were lysed in sample
buffer (56 mM sodium dodecyl sulfate, 62.5 mM Tris-HCl pH
6.8, 1.6 mM EDTA, 6.24% glycerol, trace bromophenol blue,
1 mM MgCl2 and 0.1% benzonase). Protein concentration
was measured using the DC assay (Bio-Rad) according to
manufacturer’s instructions. Lysates were run on 12% Bis-
Tris sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS–PAGE) gels (Invitrogen) and protein was transferred to a
polyvinylidene difluoride membrane (Bio-Rad) before probing
with antibodies. Primary antibodies used were SNAP25 (in-
house, 1:4000), VAMP2 (Clone 69.1, Synaptic Systems; Clone
ab181869, Abcam), synaptotagmin 1 (in-house, 1:2000), GFP
[in-house, 1:2000 (Gordon et al., 2017)]. Following incubation
with peroxidase conjugated sheep anti-mouse or donkey anti-
rabbit secondary antibodies (both 1:24000, GE Healthcare),
proteins were visualized using the SuperSignal West Dura ECL
reagent (Thermo Scientific) by X-ray film exposure with signals
quantified using ImageJ after film scanning.
Immunocytochemistry and Live Cell
Imaging
For immunocytochemistry and live cell imaging, cells were
seeded in 96-well µClear plates. For live imaging, 1 µg/ml
Hoechst 33342 stain (Life Technologies) was added for nuclear
staining. For immunocytochemistry, the cells were washed with
PBS, fixed in 4% paraformaldehyde and then permeabilised using
PBS containing 0.1% Triton X-100. Plates were then incubated in
a blocking solution (8 g BSA, 8 ml fish gelatine, 0.4 ml Tween-
20, 40 ml 10x PBS, and 8 ml normal goat serum in 400 ml) for
1 h before addition of an rabbit anti-HA antibody (R&D Systems,
1:2000) or mouse anti-GT1b antibody (Millipore, 1:500) and
incubation for 2 h at 21◦C. Following washing in PBS, cells were
incubated with DAPI stain (Sigma, 1:5000) and the Alexa Fluor
594 conjugated anti-rabbit or anti-mouse secondary antibodies
(Life Technologies) for 45 min. Cells were washed three times in
PBS before imaging with a digital fluorescence microscope (Leica
Microsystems) and a 40× objective.
Luciferase Assay
Cell extractions were performed on ice. Cells were incubated in
PBS containing 0.5% Triton-X100 and 1x SigmaFast protease
inhibitor (40 µl per well) for 10 min, then detached from the well
using a cell scraper. The suspension was incubated in a microtube
for 20 min with vortexing every 4 min. The suspension was then
centrifuged at 14,000 rpm at 4◦C for 15 min and the supernatant
was removed for storage at−20◦C until the ELISA.
For the one-step ELISA, microplate washes were performed on
a rocker (three times for 5 min at each washing stage) using PBS
and 0.05% Tween wash buffer (100 µl). Protein A coated 96 well
plates (Thermo Fisher Scientific, UK) were incubated with affinity
purified anti-cleaved VAMP2 antibody (1 µl in 50 µl PBS) and
incubated overnight at 4◦C. The plates were washed and blocking
solution (100 µl) containing PBS and 1% BSA was added to the
well and incubated for 60 min on a rocker at 21◦C. Following
washing, 45 µl cell sample was added to 120 µl wash buffer
and dispensed into two wells (50 µl each). Following a 90 min
incubation the microplate wells were washed and then incubated
with 50 µl NanoGlo solution (Promega, 4% in PBS) for 5 min in
the dark. Luminescence was read on a Fluoroskan plate reader
(Labsystems). Luminescence values for untreated and BoNT/B-
treated NanoLuc-SiMa cells were compared using the Student’s
unpaired two-tailed t-test, where ∗p ≤ 0.05 and ∗∗p ≤ 0.01.
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